Announcement no. 13/2008
To the NASDAQ OMX Nordic Exchange Copenhagen Copenhagen, August 11,
2008
Change in financial calendar
Curalogic moves forward the date of announcement of the Q2 2008 financial report
because the company wants to clearly show the value of the assets in the
Company.
The announcement of the financial report for Q3 2008 is maintained.
Below are the Company's planned dates for financial reporting in 2008:
Q2 2008: August 18, 2008
Q3 2008: November 19, 2008
For additional information, please contact:
Peter Moldt, President and CEO, Phone +45 99 99 24 01
Helle Busck Fensvig, EVP and CFO, Phone +45 99 99 24 03
About Curalogic
Curalogic is a Danish biopharmaceutical company listed on NASDAQ OMX Nordic
Exchange Copenhagen (CUR.CO) as a SmallCap+ company. Curalogic has ample cash
resources and has demonstrated its ability to conduct complex clinical studies
with a small group of development experts. Curalogic has initiated a search
process to identify development projects offering an attractive risk profile.
Curalogic expects to conclude an agreement during 2008 that will secure future
clinical development projects for the Company.
This announcement contains forward-looking statements regarding the Company's
future financial development and performance and other statements which are not
historical facts. Such statements are made on the basis of assumptions and
expectations which, to the best of the Company's knowledge and belief, are
reasonable, at this time, but may prove to be erroneous in the future.
